Trial Profile
Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications COVID-19 respiratory infection; Dyspnoea; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions
- 14 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 14 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 27 Nov 2023 Planned End Date changed from 1 Aug 2021 to 31 Dec 2023.